Clinical trial
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu…
NCT00250874 · Zeneus Pharma, Industry · Unknown status
Key facts
| NCT number | NCT00250874 |
|---|---|
| Title | Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer |
| Official title | Phase I-II Study of Liposomal Doxorubicin (Myocet®), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer |
| Lead sponsor | Zeneus Pharma, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab |
| Enrollment | 45 |
| Start date | Dec 1, 2003 |
| First posted | Nov 8, 2005 |
| Last update posted | Nov 8, 2005 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: